Terminalia para Hipoglucemia
Terminalia argentea — 3 estudios científicos revisados
Moderate¿Sirve Terminalia para hipoglucemia?
Debido a su actividad antidiabética observada en modelos de ratones, el consumo de la planta podría reducir los niveles de glucosa en sangre de forma imprevista al interactuar con las vías de regulación de la glucosa.
Compuestos activos involucrados:
Evidencia Científica
Los siguientes estudios han investigado la relación entre Terminalia y hipoglucemia:
Polyphenol-rich extract and fractions of Terminalia phaeocarpa Eichler possess hypoglycemic effect, reduce the release of cytokines, and inhibit lipase, α-glucosidase, and α-amilase enzymes.
ETHNOPHARMACOLOGICAL RELEVANCE: species of Terminalia (Combretaceae) are used to treat diabetes and metabolic disorders in Asia, Africa, and America. Terminalia phaeocarpa Eichler is an endemic tree from Brazil, popularly known as capitão. This species is closely related to Terminalia argentea Mart., also vulgarly known as capitão, a native but not endemic tree. Due to their phenotype similarity, these species might eventually prove inseparable and they are indistinctly used by locals to treat diabetes, among other diseases. The potential antidiabetic effect of T.
PubMed: 33515684Oral sub-chronic treatment with Terminalia phaeocarpa Eichler (Combretaceae) reduces liver PTP1B activity in a murine model of diabetes.
ETHNOPHARMACOLOGICAL RELEVANCE: The endemic Brazilian medicinal plants of the genus Terminalia (Combretaceae), popularly known as capitão, comprising the similar species Terminalia phaeocarpa Eichler and Terminalia argentea, are traditionally and indistinguishably used in the country to treat diabetes. AIM OF THE STUDY: The present work investigated the effect of 28 days of treatment with the crude ethanolic extract (CEE) and its derived ethyl acetate fraction (EAF) from T. phaeocarpa leaves in a mice model of diabetes. MATERIALS AND METHODS: Streptozotocin-nicotinamide-fructose diabetic model
PubMed: 36681165Chemical characterisation and toxicity assessment in vitro and in vivo of the hydroethanolic extract of Terminalia argentea Mart. leaves.
ETHNOPHARMACOLOGICAL RELEVANCE: Terminalia argentea Mart. (Combretaceae), known mainly as "capitão", is a native tree, not endemic, that occurs in the Amazon, Caatinga, Cerrado and Atlantic Forest in Brazil. Leaf infusion is popularly mentioned by riverine communities that inhabit the microregion of Northern Araguaia (Mato Grosso, Brazil) for the treatment of gastric ulcer, bronchitis and haemorrhage. Considering the wide medicinal use, lack of studies that evaluate the safety of use and the scarcity of phytochemical studies of T. argentea leaves, this work was carried out with the objective o
PubMed: 30142424Contexto Científico
Finally, research into the antidiabetic potential of the genus (specifically looking at the closely related T. argentea) explored how these extracts affect glucose levels [PMID 36681165]. Using a diabetic mouse model, researchers found that the ethanolic extract significantly reduced plasma glucose levels compared to untreated diabetic mice. The study suggested that the reduction in glucose might be linked to lowering the activity of the PTP1B enzyme in the liver.
Seguridad y Precauciones
La seguridad del uso de Terminalia argentea es un área que requiere extrema precaución debido a la naturaleza de sus compuestos bioactivos y la falta de estudios clínicos extensos en humanos. En cuanto al embarazo y la lactancia, no existe evidencia científica que garantice la seguridad del consumo de extractos de esta planta en mujeres gestantes o lactantes. Dado que estudios de genotoxicidad han mostrado que el extracto hidroetanólico de las hojas puede inducir daño en el ADN (aumento de micronúcleos y puentes nucleoplasmáticos), existe un riesgo teórico de efectos teratogénicos o alteraciones en el desarrollo fetal. No se recomienda su uso en estas etapas debido a que los compuestos fenólicos y flavonoides pueden atravesar la barrera placentaria o ser excretados en la leche materna. Para niños menores de 12 años, el uso debe evitarse estrictamente. La fisiología infantil es más susceptible a los efectos de compuestos con potencial genotóxico y a las variaciones en la actividad enzimática hepática.
Otras plantas estudiadas para Hipoglucemia
Perfil completo: Ver todos los usos y evidencia de Terminalia →